• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Newsmakers: Darren Shirley

    Are You Prepared for the 2023 DSCSA Deadline?

    Rethinking the Changing Role of the CRO

    23rd Annual Salary Survey

    Pharma 4.0 and the Modernizing Power of Digital Technology Transfer
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Ixaka & Minaris Sign Tech Transfer & GMP Manufacturing Agreement for Cell Therapy Candidate

    Pfizer, BioNTech Adapt COVID Vax Against Omicron

    CoreRx Expands Capabilities

    Pierre Fabre and Lonza Enter Manufacturing Agreement

    MasterControl and Elemental Machines Form Biomanufacturing Partnership
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    CoreRx Expands Capabilities

    Pierre Fabre and Lonza Enter Manufacturing Agreement

    Qosina Strengthens Aseptic Capabilities

    MilliporeSigma Opens $65M CDMO Facility for Cancer Therapies

    Antheia Receives $40 million in Venture Debt Financing
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Tubular Glass Primary Packaging for Pharmaceutical, Biotech and Diagnostic Containment

    How to Improve the Cold Chain System in Remote Locations

    Sentry Biopharma Services: Protecting Pharmaceutical Integrity

    Yourway to Build New Flagship European Depot

    Newsmakers: Darren Shirley
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Ixaka & Minaris Sign Tech Transfer & GMP Manufacturing Agreement for Cell Therapy Candidate

    MasterControl and Elemental Machines Form Biomanufacturing Partnership

    Charles River and Ziphius Vaccines to Manufacture saRNA-based Vaccine

    Cullinan Oncology, Taiho to Develop & Commercialize CLN-081/TAS6417 in the U.S.

    BioNTech Breaks Ground on First mRNA Vax Mfg. Facility in Africa
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Should Remote Pharma GMP Audits End After COVID?

    Why is Big Pharma Increasingly Adopting 505(b)(2)?

    Sentry Biopharma Services: Protecting Pharmaceutical Integrity

    Selkirk Pharma Appoints New Head of Quality

    Be Safer by Doing Less: The Future of Zero Touch AE Case Processing
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    IDT Biologika

    Qosina

    Biosynth Carbosynth

    Aphena Pharma Solutions

    CMC Pharmaceuticals
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    IDT Biologika

    Qosina

    Biosynth Carbosynth

    Aphena Pharma Solutions

    CMC Pharmaceuticals
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Bio News & Views

    Biopharm Executives Point to Better CMO Performance

    Better process control and increased adoption of single-use systems played a part in improving downstream manufacturing

    Related CONTENT
    • Maintaining Critical Drug Supply During COVID-19
    • Choosing and Managing a CDMO
    • A Look Into COVID Vaccines, Development and Outsourcing
    • Global Cell & Gene Therapy Mfg. Market Could Reach $57.4B by 2028
    • Covectra Enhances ATLAS Serialization Platform for Repackaging
    Eric S. Langer, BioPlan Associates, Inc.10.14.14
    Bioprocessing efficiency continues to improve, finds BioPlan Associates in its newly-released 11th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production.1 Results suggest that biomanufacturers are prioritizing manufacturing efficiency and using a number of different ways to boost productivity.

    This year, we asked global respondents to identify the single most important trend or operational area that the industry must focus on. By a clear margin, the priority was “a greater focus on manufacturing efficiency and productivity.” One in five respondents cited this as the single most important trend of the year, ahead of others such as biosimilars/biogenerics (14%), the implementation and integration of single-use systems (11%) and manufacturing cost reductions (10%). The industry believes that manufacturers and their suppliers need to increase their efforts to produce more, do it more quickly, and do so with fewer resources.

    Improving Biomanufacturing Performance
    With the emphasis on efficiency and productivity, we examined the factors contributing to performance improvements.  Grouped at the top are two leading factors: “Overall better control of processes,” cited by 73% of respondents as creating improvements; and “Use of disposable / single use devices,” cited by 72%. Roughly 6 in 10 respondents also attribute improvements to optimized cell culture processes, and better process development, with improved upstream (59%) and downstream (57%) operations also in the mix.

    We analyzed the changes during recent years in the factors that are credited with improving biomanufacturing performance. Some of the areas where we found significantly more respondents this year include:
    • “Overall better control of process”: 73% this year, vs 71% in 2013
    • “Use of disposable bags / single use devices”: cited by 72%, up from around 67% during the prior 4 years
    • “Better Design of Experiments (DoE), in process development:” 55%, up from 51% last year; and
    • “Better operations staff training”: cited by 53%, up from 49% last year.
    These areas showed appreciable increases; all other factors surveyed were cited by fewer respondents than last year or years prior. Apparently, the increased attention and investments being made in bioprocessing operations are having an impact. But it is significant that of the 15 factors identified, at least one-third of respondents reported improvements in all but one. This further confirms that bioprocessing, including its diverse processes and associated services, continues to improve.

    Gains attributed to better control of process and up- and downstream bioprocessing could be the result of increasing budgets. In last year’s study, survey respondents indicated that they would be increasing their process development budgets by an average of 5.5%, the largest percentage increase of any area measured. 2 Not far behind were planned spending increases on new technologies to improve efficiencies and costs for both upstream and downstream production (4.9% each).

    Although budget expectations this year have tampered down slightly, these areas are still seeing planned increases, with process development (4.4%) and upstream (4.2%) and downstream (4%) production operations at or near the top of respondents’ budget plans.

    For CMOs, Disposable Applications Are Most Beneficial
    We evaluated the differences in how biotherapeutic developers and CMOs perceived key performance factors. In almost each instance, CMOs were more likely to report performance improvements than biotherapeutic developers.  Indeed, of the 15 areas identified, biotherapeutic developers were more likely to see improvements from only 2: Improved upstream production operations (59% crediting with “significant” or “some” improvements, compared to 56% of CMOs); and more automated control of processes (45% vs. 33%, respectively).

    For their part, CMOs were especially more likely to attribute improvements to: 
    • Use of disposable/single-use devices (83% vs. 71%);
    • Improved downstream production operations (72% vs. 55%); and
    • Better Design of Experiements (DoE), related to process development  (72% vs. 53%).
    In fact, use of single-use devices was the area credited by the most CMOs with improving biomanufacturing performance.  

    Improving Downstream, the Persistent Bottleneck
    CMOs’ use of disposable applications to improve productivity also ties in with their improved downstream production operations. Our annual survey continues to show downstream processing being the primary remaining bioprocessing bottleneck; companies are working in different ways to de-bottleneck this issue. And perhaps not too surprisingly, CMOs are more likely than biotherapeutic developers to be turning to single-use devices to improve their downstream operations.

    To identify which activities the industry is undertaking to address downstream bottlenecks, we asked participants about specific technologies and actions their facility has actually implemented to improve those operations. We found that for nearly every implementation factor, CMOs report higher levels of adoption. This is a reflection of CMOs’ dependence on efficiency, along with their higher turnover of multiple products and ability to pass on technology implementation costs to clients.

    In an effort to predict growth in new technologies, we look to where differences between CMOs and biotherapeutic developers are largest, and to consider those few areas where developers are in front in terms of adoption.

    The survey data shows that biotherapeutic developers outstripped CMOs in their investments in downstream process development (36% vs. 18%) and in investigating alternatives to Protein A (33% vs. 18%). But while developers were more likely to investigate Protein A alternatives, it was CMOs who were far more likely to report having switched to alternatives (18% vs. 5%).

    Other similarly large discrepancies in adoption favoring CMOs include:
    Cycling columns more frequently (72.7% of CMOs vs. 54.1% of biotherapeutic developers); Using or evaluating alternative ion exchange technologies (72.7% vs. 47.5%).

    The results suggest that CMOs, by the nature of their profession, are using many different techniques to minimize bottlenecks and maximize capacity from their facilities. In this sense, CMOs more resemble the clinical facilities of product developers which must, by design, be more flexible to handle a diversity of processes. The data also shows that for CMOs, use of disposable applications is being credited with downstream processing improvements, which in turn are leading to overall biomanufacturing performance improvements.

    Despite those improvements, downstream processing continues to rile both CMOs and biomanufacturers. This year, respondents were again asked to describe the impact their downstream purification processes were having on their overall capacity. We found that 69% of respondents (vs. 76% last year, 72% in 2012, and 69% in 2011) reported at least some degree of capacity bottleneck at their facility as a result of downstream processes.

    In fact, the impact of downstream bottlenecks may be on the rise. We found a year-over-year increase in both the proportion of respondents experiencing “serious bottlenecks today” (8% vs. 7%) and “some bottleneck problems” (37% vs. 29%). By contrast, the percentage expecting “no bottlenecks” remained relatively flat at 23%. Downstream issues and production constraints appear to be a chronic complaint.

    The percentage of CMOs and biodevelopers reporting “serious” or “some” capacity problems due to downstream processing both increased from last year. While no CMOs reported “serious” bottlenecks today, 6 in 10 claimed to have had “some,” the highest level since our 2009 study.

    CMOs’ experiences are often harbingers of what’s to come. If this year’s large increase in downstream-blamed bottlenecks is indeed a leading indicator in bioprocessing efficiency, this suggests a trend that downstream problems will be further increasing for developers too. In the context of CMOs having to work with many more products, it would not be surprising if they reported higher downstream bottlenecks and concerns. But it is the nature of CMO business not to assume tasks for which they lack needed resources.

    It seems clear that CMOs are taking the lead in evaluating new technologies. Our study separately found that CMOs were considering a range of new downstream processing solutions at a greater rate than their biotherapeutic developer counterparts. Those include a host of disposable applications, including various single-use filters, disposable UF systems and single-use prepacked columns. Similarly, when we surveyed new product development areas of interest, CMOs were more vocal in their interest in the majority of areas, with disposable purification in particular emerging as one of their key interests, indicated to be among their Top-Five by a majority of CMO respondents. So while CMOs reported more widespread capacity bottlenecks than biotherapeutic developers this year, CMOs are actively searching for and trialing new technologies with the potential to improve productivity. 

    What’s Next in Bioprocessing Efficiency
    The industry is maturing and now finds itself acutely aware of the need for new technologies to optimize, and in some cases revolutionize existing processes. Yet, while end-users still actively look for new technologies to solve persistent problems, these changes are underpinned by very specific needs. Approaches that shorten the time to get facilities up and running and reduce capital investments are mandatory for new facility design. Similarly, the industry is demanding better downstream processes—demands that generally focus on cheaper and more effective chromatography and purification steps.

    The biopharmaceutical industry—and CMOs in particular—are continuing to invest in improved manufacturing methods, particularly concerning process control and optimization. Surprisingly, responses to these questions varied between product manufacturers and CMOs, with the former reporting more frequent implementation of process-related improvements. One might expect CMOs, with their high project turnover and need to do it right quickly and the first time, to be out in front of product manufacturers in terms of implementing process improvements. But many CMOs prefer to standardize their bioprocessing, and many follow the regulatory and manufacturing-related requirements of their clients.

    CMOs are leading the way in disposables adoption, though, and appear to be satisfied with the results, crediting their disposables use with significant improvements in downstream processing and overall biomanufacturing performance. As single-use applications continue to penetrate biopharmaceutical manufacturing and the market for these applications mature, a number of trends can be expected:
    • More quality will be built into single-use systems to attempt to further reduce regulatory activities and oversight;
    • More single-use downstream operations will include membrane adsorbers;
    • Better standards for leachables and extractables testing will emerge; and
    • Problems surrounding disposable devices that are creating inconsistent growth due to changes in resins and cell line specificity, among others, will be addressed.
    One can reasonably expect CMOs to continue at the forefront, pushing these changes—and benefiting from them. 

    References
    1. 11th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production:  A Survey of Biotherapeutic Developers and Contract Manufacturing Organizations, BioPlan Associates, April 2014. www.bioplanassociates.com/11th

    Eric S. Langer
    BioPlan Associates, Inc.

    Eric S. Langer is president and managing partner at BioPlan Associates, Inc., a biotechnology and life sciences marketing research and publishing firm established in Rockville, MD in 1989. He is editor of numerous studies, including “Biopharmaceutical Technology in China,” “Advances in Large-scale Biopharmaceutical Manufacturing”, and many other industry reports.  elanger@bioplanassociates.com  301-921-5979.  www.bioplanassociates.com
    Related Searches
    • Testing
    • study
    • Development
    • leachables
    Suggested For You
    Maintaining Critical Drug Supply During COVID-19 Maintaining Critical Drug Supply During COVID-19
    Choosing and Managing a CDMO Choosing and Managing a CDMO
    A Look Into COVID Vaccines, Development and Outsourcing A Look Into COVID Vaccines, Development and Outsourcing
    Global Cell & Gene Therapy Mfg. Market Could Reach $57.4B by 2028 Global Cell & Gene Therapy Mfg. Market Could Reach $57.4B by 2028
    Covectra Enhances ATLAS Serialization Platform for Repackaging Covectra Enhances ATLAS Serialization Platform for Repackaging
    Clinical to Commercial Manufacturing: Selecting the Right CDMO for Your Sterile Drug Product Clinical to Commercial Manufacturing: Selecting the Right CDMO for Your Sterile Drug Product
    Maintaining Critical Drug Supply During the Pandemic Maintaining Critical Drug Supply During the Pandemic
    ProCell for Patient Project to Develop Automated Production Unit for CAR-T Cell Therapies ProCell for Patient Project to Develop Automated Production Unit for CAR-T Cell Therapies
    The Word ‘Innovation’ Probably Doesn’t Mean What You Think It Does The Word ‘Innovation’ Probably Doesn’t Mean What You Think It Does
    CDMO Market Trends & Opportunities CDMO Market Trends & Opportunities
    The Ever-Evolving World of Combination Products The Ever-Evolving World of Combination Products
    Embedding Your Drug Strategy Within a Solid Foundation for Success Embedding Your Drug Strategy Within a Solid Foundation for Success
    Sepha Launches Small Batch Contract Packaging Service Sepha Launches Small Batch Contract Packaging Service
    A Potential “Marriage” A Potential “Marriage”
    Injectables Firms Expand Capacity Injectables Firms Expand Capacity

    Related Content

    • Logistics | Supply Chain
      Maintaining Critical Drug Supply During COVID-19

      Maintaining Critical Drug Supply During COVID-19

      Vincent Colicchio from Dr. Reddy’s talks about the challenges and solutions of maintaining supply during the pandemic.
      Tim Wright, Editor, Contract Pharma 09.09.21

    • Choosing and Managing a CDMO

      Choosing and Managing a CDMO

      Speed up your time-to-market, keep development costs under control and smooth the FDA approval and commercial launch process.
      Dana Toops, President, Avema Pharma Solutions 09.09.21

    • Biologics, Proteins, Vaccines | cGMP Manufacture
      A Look Into COVID Vaccines, Development and Outsourcing

      A Look Into COVID Vaccines, Development and Outsourcing

      Fiona Barry of PharmSource discusses COVID vaccines in development and CMO outsourcing trends.
      08.09.21


    • Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Industry News
      Global Cell & Gene Therapy Mfg. Market Could Reach $57.4B by 2028

      Global Cell & Gene Therapy Mfg. Market Could Reach $57.4B by 2028

      Market estimated to grow at CAGR of 20% from 2021 to 2028 due to an exponential rise in clinical pipeline along with rising number of regulatory approvals.
      07.30.21

    • Reader Showcase | Serialization
      Covectra Enhances ATLAS Serialization Platform for Repackaging

      Covectra Enhances ATLAS Serialization Platform for Repackaging

      Designed to simplify the repackaging of pre-serialized pharmaceutical products.
      07.19.21

      Loading, Please Wait..
      Trending
      • Pierre Fabre And Lonza Enter Manufacturing Agreement
      • 17th Annual Contracting & Outsourcing Conference Photos
      • Regulatory Report: Analytical Procedure Development
      • Machine Learning-based Predictive Modeling: Notable Uses In Clinical Trials
      • MilliporeSigma Opens $65M CDMO Facility For Cancer Therapies
      Breaking News
      • Ixaka & Minaris Sign Tech Transfer & GMP Manufacturing Agreement for Cell Therapy Candidate
      • Pfizer, BioNTech Adapt COVID Vax Against Omicron
      • CoreRx Expands Capabilities
      • Qosina Strengthens Aseptic Capabilities
      • Charles River and Ziphius Vaccines to Manufacture saRNA-based Vaccine
      View Breaking News >
      CURRENT ISSUE

      June 2022

      • Newsmakers: Darren Shirley
      • Are You Prepared for the 2023 DSCSA Deadline?
      • Rethinking the Changing Role of the CRO
      • 23rd Annual Salary Survey
      • Pharma 4.0 and the Modernizing Power of Digital Technology Transfer
      • CEO Spotlight: David Chang
      • Changes are on the Horizon for Single-use Systems in Pharmaceutical Manufacturing
      • CRO Industry Market Report

      Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
      You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

      • About Us
      • Privacy Policy
      • Terms And Conditions
      • Contact Us

      follow us

      Subscribe
      Nutraceuticals World

      Latest Breaking News From Nutraceuticals World

      Japanese Mushroom Extract Appears Helpful in HPV Infections
      Fi & Hi Europe Returns with Over 20,000 Global Attendees Expected
      United Plant Savers Launches First Film Festival
      Coatings World

      Latest Breaking News From Coatings World

      H.M. Royal Becomes Exclusive OCSiAl Distributor
      American Colors to Expand Sandusky, Ohio Facility
      Vaughn O’Dea Named Director of Epoxytec
      Medical Product Outsourcing

      Latest Breaking News From Medical Product Outsourcing

      Siemens' Varian Gains FDA IDE Nod for FAST-02 Trial
      Acutus Medical Launches AcQCross Line Extension
      Accelmed Partners II, Lauxera Capital Partners Invest in Veranex
      Contract Pharma

      Latest Breaking News From Contract Pharma

      Ixaka & Minaris Sign Tech Transfer & GMP Manufacturing Agreement for Cell Therapy Candidate
      Pfizer, BioNTech Adapt COVID Vax Against Omicron
      CoreRx Expands Capabilities
      Beauty Packaging

      Latest Breaking News From Beauty Packaging

      Top 5 Beauty Tech Trends at Perfect Corp.'s Global Forum
      John Frieda Supports the LGBTQIA+ Community
      Athena Club Launches in Canada
      Happi

      Latest Breaking News From Happi

      Past Henkel Exec Christian Chopra Named President of Scotch Porter
      Color Street Celebrates Foster, Adoption Awareness with Limited-Edition Print
      CIR Panel Conducts 161st Meeting Regarding Safety Assessments for Cosmetic Ingredients
      Ink World

      Latest Breaking News From Ink World

      Dr. Tammo Boinowitz to Join Management Board of ALTANA AG
      Flint Offset Packaging Solutions Announces Price Increases for Sheetfed Inks
      Weekly Recap: INX’s VC Fund, Screen Industry and Ball Top This Week’s News
      Label & Narrow Web

      Latest Breaking News From Label & Narrow Web

      Harveer Sahni recognized with Global Achievement Award
      Color-Logic partners with Taktiful 
      ALTANA announces Management Board change
      Nonwovens Industry

      Latest Breaking News From Nonwovens Industry

      Fibertex Personal Care Awarded EcoVadis Awards for Sustainability
      Yanpai Orders Batt Forming Equipment for Needlepunch Line
      Weekly Recap: SWM and Neenah Introduce Mativ Inc., Avgol honored for Biotransformation Technology & More
      Orthopedic Design & Technology

      Latest Breaking News From Orthopedic Design & Technology

      Researchers Discover Novel Patching Material for Bone Defects
      Boston Centerless Opens Second Manufacturing Plant in Indiana
      Researchers Develop Patient-Specific 3D-Printed Smart Metamaterial Implants
      Printed Electronics Now

      Latest Breaking News From Printed Electronics Now

      Identiv-Powered CVS Spoken Rx Wins NFC Forum 2022 Innovation Award
      LG Display Announces Winners of This Year’s OLEDs GO! Competition
      Weekly Recap: eMagin, Applied Materials, and Schott Top This Week’s Stories

      Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

      AD BLOCKER DETECTED

      Our website is made possible by displaying online advertisements to our visitors.
      Please consider supporting us by disabling your ad blocker.


      FREE SUBSCRIPTION Already a subscriber? Login